Therapeutic Controversy in Differentiated Thyroid Cancer and the Need for a Clinical Protocol

Thyroid cancer accounts for less than 1.5 % of all cases of malignancy. Over 85 % were found to be a differentiated thyroid cancer (papillary, follicular, Hurthle cell). While differentiated thyroid cancer remains one of the most curable of all cancers, patients with aggressive tumors are occasionally seen. The role of prognostic factors in guiding therapeutic decision is becoming more important, these are like patient- related factors and tumor-related factors. However, management of differentiated thyroid cancer continued to be controversial; especially in relation to the role of radioiodine therapy and the recommended doses.